Praeventix, LLC
5-HT7 receptor antagonist small-molecule therapeutics for chronic pruritus and serotonergic disorders
- Sector
- Biotech
- Headquarters
- Exton, PA
- Founded
- 2022
- Latest Form D
- $3M, Feb 2026
- Total capital
- $22.1M
- Federal grants
- $9.9M
- 12 awards · 2017–2026
- Rank in peer group#52 of 514
- Private capital raised
- $12.1M
- 3 Form D · last Feb 2026
- 8 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 12 pending · first 2020
- Rank in peer group#85 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder$355K
- Private capital raisedForm D · SEC · 3rd filing$3M
- Private capital raisedForm D · SEC · 2nd filing$6.8M
- Federal grantHealth and Human S · Phase II · IND Enabling Studies for the Development of Pruritus Therapeutic PRA-523$728K
- Federal grantHealth and Human S · Phase II · In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder$1.3M
- Federal grantHealth and Human S · Phase II · IND Enabling Studies for the Development of Pruritus Therapeutic PRA-523$1.2M
- Federal grantHealth and Human S · Phase II · In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder$1.3M
- Private capital raisedForm D · SEC · 1st filing$2.3M
Show 7 earlier federal awards
- Federal grantHealth and Human S · Phase I · Novel 5-HT7 Antagonists for the Treatment of Pruritus$276K
- Federal grantHealth and Human S · Phase II · In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder$320K
- Federal grantHealth and Human S · Phase I · In vivo Characterization of PRA078C in the Rat Cocaine Reinstatement Model$350K
- Federal grantHealth and Human S · Phase II · Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease$1.2M
- Federal grantHealth and Human S · Phase II · Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease$2.5M
- Federal grantHealth and Human S · Phase I · Novel HT Antagonists for the treatment of inflammatory bowel disease$232K
- Federal grantHealth and Human S · Phase I · Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease$232K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
63months
from Praeventix, LLC’s first federal award to its first private round.
- First federal award · Aug 2017
- Health and Human S · $232K
- First Form D · Nov 2022
- $2.3M · 1st Form D
- Awards before first raise
- 7 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#52 · top 10%
- Granted patents#85 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Douglas A. PippinResearcherExecutive Officer, DirectorLinked by $3.9M in grants as PI
- Douglas A. Pippin, PhDExecutive Officer, DirectorNamed in SEC Form D filings
- Heidi O. KempinskiExecutive Officer, DirectorNamed in SEC Form D filings
- Leonard O. Moulder, Jr.DirectorNamed in SEC Form D filings
- Leon O. MoulderDirectorNamed in SEC Form D filings
- Leon O. Moulder, Jr.DirectorNamed in SEC Form D filings
Show all 7 people
- Robert S. HankinDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 16- PendingNovel Functionalized Lactams As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseUSPTOApplication 19390312
- PendingFunctionalized Lactams As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseUSPTOApplication 19390298
- GrantedNovel Functionalized Lactams As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseUSPTOUS 12,559,494
Show all 16 patent records
- Novel Functionalized Lactams As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseMar 12, 2026 · Application 19390312Pending
- Functionalized Lactams As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseMar 12, 2026 · Application 19390298Pending
- Novel Functionalized Lactams As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseFeb 24, 2026 · US 12,559,494Granted
- Novel Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseSep 11, 2025 · Application 19213974Pending
- Novel Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseJun 24, 2025 · US 12,338,247Granted
- Novel Functionalized Lactones As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseJan 26, 2023 · Application 17776531Pending
- Novel Functionalized Lactams As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseJan 5, 2023 · Application 17776533Pending
- Novel Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseMay 3, 2022 · US 11,319,327Granted
- Novel Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseDec 8, 2020 · US 10,858,368Granted
- Novel Functionalized Lactones As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseApplication PCTUS2020060271Pending
- Novel Functionalized Lactams As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseApplication 62934997Pending
- Novel Functionalized Lactones As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseApplication 62934985Pending
- Novel Functionalized Lactams As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseApplication 62670116Pending
- Novel Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseApplication PCTUS2017061677Pending
- Novel Functionalized Lactams As Modulators Of The 5-HYDROXYTRYPTAMINE Receptor 7 And Their Method Of UseApplication PCTUS2020060270Pending
- Novel Modulators of the 5-Hydroxytryptamine Receptor 7 and Their Method of UseApplication 62422344Pending
Related companies, and why
- COURAGENE, INC.Similar federal contract value in Biotech · null in contracts
- SUNFLOWER THERAPEUTICS PBCSimilar federal contract value in Biotech · null in contracts
- NiKang TherapeuticsSimilar federal contract value in Biotech · null in contracts
- ABILITA BIO, INC.Similar federal contract value in Biotech · null in contracts
- ACELOT, INC.Similar federal contract value in Biotech · null in contracts
- DeuteRx LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .